Cramer's lightning round: 'I'm going to say yes to Jazz Pharmaceuticals'

Source

In this article

Stock Chart Icon Stock chart icon
hide content
Corteva's year-to-date stock performance.

Corteva: "There is absolutely no reason you would want to own this one over Vylor."

Stock Chart Icon Stock chart icon
hide content
Onto Innovation's year-to-date stock performance.

Onto Innovation: "We're going to take a harder look at Onto because it's another one of these companies that's process control solutions, and they're all really hard to understand."

Stock Chart Icon Stock chart icon
hide content
Apple Hospitality REIT's year-to-date stock performance.

Apple Hospitality REIT: "If I think rates are going to 6%, then I can't own that stock. You're going to end up losing money if you buy that stock. And I think rates will go to 6%."

Stock Chart Icon Stock chart icon
hide content
EchoStar's year-to-date stock performance.

EchoStar: "I read today a very informative piece about how EchoStar could get a bid from SpaceX, and it was very compelling. I've not liked the stock, but I certainly cannot be oblivious to that takeover."

Stock Chart Icon Stock chart icon
hide content
Jazz Pharmaceuticals' year-to-date stock performance.

Jazz Pharmaceuticals: "You're starting to go into a very speculative situation where they actually do make money, though. I'm going to say yes to Jazz Pharmaceuticals."

Jim Cramer's Guide to Investing

Click here to read Jim Cramer's Guide to Investing at no cost to help you build long-term wealth and invest smarter

Sign up now for the CNBC Investing Club to follow Jim Cramer's every move in the market.

Disclaimer

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer's world? Hit him up!
Mad Money Twitter - Jim Cramer Twitter - Facebook - Instagram

Questions, comments, suggestions for the "Mad Money" website? madcap@cnbc.com

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.